{"url_path":"/sec/bfriw/8-k/2026-06-17/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1858685/0001493152-26-029079-index.html","accession_number":"0001493152-26-029079","cik":"0001858685","ticker":"BFRI","issuer_name":"Biofrontera Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1858685/0001493152-26-029079-index.html","primary_entity_key":"0001858685","primary_entity_name":"Biofrontera Inc."},"word_count":332,"has_tables":true,"body_markdown":"**Item\n5.07 Submission of Matters to a Vote of Security Holders**\n\n \n\nOn\nJune 11, 2026, Biofrontera Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”).\nProxies for the Annual Meeting were solicited pursuant to Regulation 14A under the Securities Exchange Act of 1934, and there was no\nsolicitation in opposition to the Company’s solicitation. Details of the proposals voted on at the Annual Meeting are described\nin the Proxy Statement filed by the Company with the Securities and Exchange Commission on April 30, 2026. There were present at the\nAnnual Meeting holders of shares representing 11,630,133 votes, constituting a quorum. The following summarizes all matters voted on\nat the Annual Meeting.\n\n \n\n1.\nStockholders elected Beth J. Hoffman, Ph.D. and Kevin D. Weber to serve as Class II directors of the Company until the 2029 Annual Meeting\nof Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or\nremoval. The tabulation of votes cast was as follows:\n\n \n\n**Beth\nJ. Hoffman, Ph.D.**\n\n** **\n\nFor  \nWithheld  \nBroker Non-Votes \n\n8,089,416  \n 221,060  \n 3,319,657 \n\n \n\n**Kevin\nD. Weber**\n\n \n\nFor  \nWithheld  \nBroker Non-Votes \n\n8,203,433  \n 107,043  \n 3,319,657 \n\n \n\n2.\nStockholders approved the amendment and restatement of the Company’s 2021 Omnibus Incentive Plan, including to increase the total\nnumber of shares of common stock authorized thereunder from 3,750,000 to 8,750,000. The tabulation of votes cast was as follows:\n\n \n\nFor  \nAgainst  \nAbstain  \nBroker Non-Votes \n\n7,893,236  \n 241,359  \n 175,881  \n 3,319,657 \n\n \n\n3.\nStockholders ratified the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the\nfiscal year ending December 31, 2026. The tabulation of votes cast was as follows:\n\n** **\n\nFor  \nAgainst  \nAbstain  \nBroker Non-Votes \n\n10,905,016  \n 723,806  \n 1,311  \n 0 \n\n \n\n \n\n \n\n** **\n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n**June\n17, 2026**\n**Biofrontera\nInc.**\n\n(Date)\n(Registrant)\n\n \n \n\n \n*/s/\nE. Fred Leffler III*\n\n \nE.\nFred Leffler III\n\n \n*Chief\nFinancial Officer*"}